Why Submit to Blood?



  • In continuous publication since 1946, Blood is THE #1 cited journal in the field of hematology.
  • With an average of 460 references daily, Blood is the best vehicle for reaching the hematology realm.
  • Blood editors are experts within the field of hematology and manuscripts are reviewed by prominent specialists.


Quick Decisions
15 Days
from Submission to 1st Decision (average for unsolicited submissions)
Quick Publication
11 Days from Acceptance to First Edition (average for unsolicited submissions)
Citation Reach
Blood articles were cited 167,858 times in 2017 (#1 in hematology & 23rd overall)
This Week in Blood
A newsletter featuring the hottest studies, selected by the Editor-in-Chief and Deputy Editor
Blood Journals App
Highly rated mobile app available through the Apple App Store (4.5) and Google Play (4.4)
Highly Cited
Over 10,500 articles published in the last 11 years have been cited 10 or more times
Google Scholar
Blood is the #1 rated publication by Google Scholar in the hematology category
Eigenfactor® Score
With a score of .27804, Blood is #1 in hematology and 27th overall
ASH Press Release Program
Selected articles are promoted using a targeted strategy to media outlets and journalists
Article Alerts
Request an alert informing you that your article has been cited and/or commented on
"Written in Blood"
Prominent clinical research papers published in Blood are highlighted in the ASH Clinical News
Limited Revisions
On average, accepted papers go through no more than 2 rounds of revision.


" I publish in Blood because of the impact the journal has on influencing practice and subsequent research, and because I know the findings from my research will be disseminated quickly." Mikkael Sekeres MD, MS, Professor of Medicine, Cleveland Clinic


How to Get Published in a Peer-Reviewed Journal: Presentation

Bob Löwenberg, MD, PhD
Blood Editor-in-Chief
Erasmus University Medical Center
Rotterdam, the Netherlands


Author Voices: Brad Kahl, MD

Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., … Wagner-Johnston, N. D. (2014). A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood, 123(22), 3398–3405.